APO Research
Talk to an analyst

APO RESEARCH · REPORT

Children Influenza Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Children Influenza Vaccine Market Outlook and Growth Opportunities 2026

30 December 2025193 pages

Choose your research edition.

Industry ResearchChildren Influenza Vaccine Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Children Influenza Vaccine Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Children Influenza Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Children Influenza Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Children Influenza Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Children Influenza Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Children Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Children Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Children Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Children Influenza Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Children Influenza Vaccine market include BCHT, CCBIO, CSL, Hulan Bio, KM Biologics, Sanofi Pasteur, Sinovac, Viatris and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Children Influenza Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Children Influenza Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Children Influenza Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Children Influenza Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Children Influenza Vaccine Segment by Company

BCHT

CCBIO

CSL

Hulan Bio

KM Biologics

Sanofi Pasteur

Sinovac

Viatris

AstraZeneca

GSK

Jiangsu GDK

Children Influenza Vaccine Segment by Type

Nasal Spray

Injection

Children Influenza Vaccine Segment by Application

Public

Private

Children Influenza Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Children Influenza Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Children Influenza Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Children Influenza Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Children Influenza Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Children Influenza Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Children Influenza Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Children Influenza Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Children Influenza Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Children Influenza Vaccine industry.

Chapter 3: Detailed analysis of Children Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Children Influenza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Children Influenza Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Children Influenza Vaccine Industry Trends Table 2. Children Influenza Vaccine Industry Drivers Table 3. Children Influenza Vaccine Industry Opportunities and Challenges Table 4. Children Influenza Vaccine Industry Restraints Table 5. Global Children Influenza Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Children Influenza Vaccine Revenue Share by Company (2021-2026) Table 7. Global Children Influenza Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Children Influenza Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Children Influenza Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Children Influenza Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Children Influenza Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Children Influenza Vaccine Company, Product Type & Application Table 13. Global Children Influenza Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Children Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Nasal Spray Table 18. Significant Companies of Injection Table 19. Global Children Influenza Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Children Influenza Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Children Influenza Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Children Influenza Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Children Influenza Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Children Influenza Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Children Influenza Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Children Influenza Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Children Influenza Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Children Influenza Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Public Table 30. Significant Companies of Private Table 31. Global Children Influenza Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Children Influenza Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Children Influenza Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Children Influenza Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Children Influenza Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Children Influenza Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Children Influenza Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Children Influenza Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Children Influenza Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Children Influenza Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Children Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Children Influenza Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Children Influenza Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Children Influenza Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Children Influenza Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Children Influenza Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Children Influenza Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Children Influenza Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Children Influenza Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Children Influenza Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Children Influenza Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Children Influenza Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Children Influenza Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Children Influenza Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Children Influenza Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Children Influenza Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Children Influenza Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Children Influenza Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Children Influenza Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Children Influenza Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Children Influenza Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Children Influenza Vaccine Sales Value Market Share by Country (2027-2032) Table 63. BCHT Company Information Table 64. BCHT Business Overview Table 65. BCHT Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. BCHT Children Influenza Vaccine Product Portfolio Table 67. BCHT Recent Development Table 68. CCBIO Company Information Table 69. CCBIO Business Overview Table 70. CCBIO Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. CCBIO Children Influenza Vaccine Product Portfolio Table 72. CCBIO Recent Development Table 73. CSL Company Information Table 74. CSL Business Overview Table 75. CSL Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. CSL Children Influenza Vaccine Product Portfolio Table 77. CSL Recent Development Table 78. Hulan Bio Company Information Table 79. Hulan Bio Business Overview Table 80. Hulan Bio Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Hulan Bio Children Influenza Vaccine Product Portfolio Table 82. Hulan Bio Recent Development Table 83. KM Biologics Company Information Table 84. KM Biologics Business Overview Table 85. KM Biologics Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. KM Biologics Children Influenza Vaccine Product Portfolio Table 87. KM Biologics Recent Development Table 88. Sanofi Pasteur Company Information Table 89. Sanofi Pasteur Business Overview Table 90. Sanofi Pasteur Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sanofi Pasteur Children Influenza Vaccine Product Portfolio Table 92. Sanofi Pasteur Recent Development Table 93. Sinovac Company Information Table 94. Sinovac Business Overview Table 95. Sinovac Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Sinovac Children Influenza Vaccine Product Portfolio Table 97. Sinovac Recent Development Table 98. Viatris Company Information Table 99. Viatris Business Overview Table 100. Viatris Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Viatris Children Influenza Vaccine Product Portfolio Table 102. Viatris Recent Development Table 103. AstraZeneca Company Information Table 104. AstraZeneca Business Overview Table 105. AstraZeneca Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. AstraZeneca Children Influenza Vaccine Product Portfolio Table 107. AstraZeneca Recent Development Table 108. GSK Company Information Table 109. GSK Business Overview Table 110. GSK Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. GSK Children Influenza Vaccine Product Portfolio Table 112. GSK Recent Development Table 113. Jiangsu GDK Company Information Table 114. Jiangsu GDK Business Overview Table 115. Jiangsu GDK Children Influenza Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Jiangsu GDK Children Influenza Vaccine Product Portfolio Table 117. Jiangsu GDK Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Children Influenza Vaccine Distributors List Table 121. Children Influenza Vaccine Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Children Influenza Vaccine Product Image Figure 2. Global Children Influenza Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Children Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Children Influenza Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Children Influenza Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Children Influenza Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Nasal Spray Image Figure 10. Injection Image Figure 11. Global Children Influenza Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Children Influenza Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Children Influenza Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Children Influenza Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Children Influenza Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Children Influenza Vaccine Sales Value Share by Type (2021-2032) Figure 17. Public Image Figure 18. Private Image Figure 19. Global Children Influenza Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Children Influenza Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Children Influenza Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Children Influenza Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Children Influenza Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Children Influenza Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Children Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Children Influenza Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Children Influenza Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Children Influenza Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Children Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Children Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Children Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Children Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Children Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Children Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Children Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Children Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Children Influenza Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Children Influenza Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Children Influenza Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Children Influenza Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Children Influenza Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Nasal Spray
  • Injection
Applications
  • Public
  • Private
Companies covered
  • BCHT
  • CCBIO
  • CSL
  • Hulan Bio
  • KM Biologics
  • Sanofi Pasteur
  • Sinovac
  • Viatris
  • AstraZeneca
  • GSK
  • Jiangsu GDK

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Children Influenza Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Children Influenza Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Children Influenza Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Children Influenza Vaccine Market Dynamics
  1. 2.1 Children Influenza Vaccine Industry Trends
  2. 2.2 Children Influenza Vaccine Industry Drivers
  3. 2.3 Children Influenza Vaccine Industry Opportunities and Challenges
  4. 2.4 Children Influenza Vaccine Industry Restraints
3 Children Influenza Vaccine Market by Company
  1. 3.1 Global Children Influenza Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Children Influenza Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Children Influenza Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Children Influenza Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Children Influenza Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Children Influenza Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Children Influenza Vaccine Company Product Type and Application
  8. 3.8 Global Children Influenza Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Children Influenza Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Children Influenza Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Children Influenza Vaccine Market by Type
  1. 4.1 Children Influenza Vaccine Type Introduction
  2. 4.1.1 Nasal Spray
  3. 4.1.2 Injection
  4. 4.2 Global Children Influenza Vaccine Sales Volume by Type
  5. 4.2.1 Global Children Influenza Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Children Influenza Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Children Influenza Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Children Influenza Vaccine Sales Value by Type
  9. 4.3.1 Global Children Influenza Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Children Influenza Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Children Influenza Vaccine Sales Value Share by Type (2021-2032)
5 Children Influenza Vaccine Market by Application
  1. 5.1 Children Influenza Vaccine Application Introduction
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Children Influenza Vaccine Sales Volume by Application
  5. 5.2.1 Global Children Influenza Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Children Influenza Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Children Influenza Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Children Influenza Vaccine Sales Value by Application
  9. 5.3.1 Global Children Influenza Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Children Influenza Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Children Influenza Vaccine Sales Value Share by Application (2021-2032)
6 Children Influenza Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Children Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Children Influenza Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Children Influenza Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Children Influenza Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Children Influenza Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Children Influenza Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Children Influenza Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Children Influenza Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Children Influenza Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Children Influenza Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Children Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Children Influenza Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Children Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Children Influenza Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Children Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Children Influenza Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Children Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Children Influenza Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Children Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
7 Children Influenza Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Children Influenza Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Children Influenza Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Children Influenza Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Children Influenza Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Children Influenza Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Children Influenza Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Children Influenza Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Children Influenza Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Children Influenza Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Children Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Children Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BCHT
  2. 8.1.1 BCHT Company Information
  3. 8.1.2 BCHT Business Overview
  4. 8.1.3 BCHT Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 BCHT Children Influenza Vaccine Product Portfolio
  6. 8.1.5 BCHT Recent Developments
  7. 8.2 CCBIO
  8. 8.2.1 CCBIO Company Information
  9. 8.2.2 CCBIO Business Overview
  10. 8.2.3 CCBIO Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CCBIO Children Influenza Vaccine Product Portfolio
  12. 8.2.5 CCBIO Recent Developments
  13. 8.3 CSL
  14. 8.3.1 CSL Company Information
  15. 8.3.2 CSL Business Overview
  16. 8.3.3 CSL Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CSL Children Influenza Vaccine Product Portfolio
  18. 8.3.5 CSL Recent Developments
  19. 8.4 Hulan Bio
  20. 8.4.1 Hulan Bio Company Information
  21. 8.4.2 Hulan Bio Business Overview
  22. 8.4.3 Hulan Bio Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hulan Bio Children Influenza Vaccine Product Portfolio
  24. 8.4.5 Hulan Bio Recent Developments
  25. 8.5 KM Biologics
  26. 8.5.1 KM Biologics Company Information
  27. 8.5.2 KM Biologics Business Overview
  28. 8.5.3 KM Biologics Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 KM Biologics Children Influenza Vaccine Product Portfolio
  30. 8.5.5 KM Biologics Recent Developments
  31. 8.6 Sanofi Pasteur
  32. 8.6.1 Sanofi Pasteur Company Information
  33. 8.6.2 Sanofi Pasteur Business Overview
  34. 8.6.3 Sanofi Pasteur Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Pasteur Children Influenza Vaccine Product Portfolio
  36. 8.6.5 Sanofi Pasteur Recent Developments
  37. 8.7 Sinovac
  38. 8.7.1 Sinovac Company Information
  39. 8.7.2 Sinovac Business Overview
  40. 8.7.3 Sinovac Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sinovac Children Influenza Vaccine Product Portfolio
  42. 8.7.5 Sinovac Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Children Influenza Vaccine Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Children Influenza Vaccine Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 GSK
  56. 8.10.1 GSK Company Information
  57. 8.10.2 GSK Business Overview
  58. 8.10.3 GSK Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 GSK Children Influenza Vaccine Product Portfolio
  60. 8.10.5 GSK Recent Developments
  61. 8.11 Jiangsu GDK
  62. 8.11.1 Jiangsu GDK Company Information
  63. 8.11.2 Jiangsu GDK Business Overview
  64. 8.11.3 Jiangsu GDK Children Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Jiangsu GDK Children Influenza Vaccine Product Portfolio
  66. 8.11.5 Jiangsu GDK Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Children Influenza Vaccine Value Chain Analysis
  2. 9.1.1 Children Influenza Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Children Influenza Vaccine Sales Mode & Process
  6. 9.2 Children Influenza Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Children Influenza Vaccine Distributors
  9. 9.2.3 Children Influenza Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst